UK On Cusp Of Integrated Care And New Regulatory Fees But Innovation Adoption Pressures Remain
UK patients see benefits of AI but medtech industry must take heed of changes ushered in by new Health and Care Act
New medtech regulatory policy, technology adoption challenges and NHS architecture changes under the new Health and Care Act will give system UK users much to ponder over this summer.
You may also be interested in...
The spotlight is on IVDs in the post-COVID phase. Innovators in university spin-outs and the established industry have responded with new technologies, creating a vibrant scene. Regulators and reimbursors must not disrupt the momentum, say BIVDA’s regulatory affairs manager Ashleigh Batchen and chief executive Doris-Ann Williams.
The pressures on global medtechs to focus more on sustainability are internal as well as external. Scope 3 adds yet another layer of compliance. Johnson & Johnson’s EMEA VP for Surgical Vision Erin McEachren explains to In Vivo how her organization meets these challenges while simultaneously addressing EU Medical Device Regulation requirements and ensuring patient safety standards.
As the health care sector moves from linear to circular, medtechs, providers and patients all have roles to play in ensuring that current strategies, practices and behaviors contribute to guarantee a sustainable future. Part one of a short series on this theme looks as best practice for providers.